The emergence and spread of multidrug-resistant Plasmodium falciparum compromises the treatment of malaria, especially during pregnancy, where the choice of antimalarials is already limited. Artesunate (n p ) or artemether ( ) was used to treat 539 episodes of acute P. falciparum malaria in 461 pregnant 528 n p 11 women, including 44 first-trimester episodes. Most patients (310 [57.5%]) received re-treatments after earlier treatment with quinine or mefloquine. By use of survival analysis, the cumulative artemisinin failure rate for primary infections was 6.6% (95% confidence interval, 1.0-12.3), compared with the re-treatment failure rate of 21.7% (95% confidence interval, 15.4-28.0; ). The artemisinins were well tolerated with no evidence P p .004 of adverse effects. Birth outcomes did not differ significantly to community rates for abortion, stillbirth, congenital abnormality, and mean gestation at delivery. These results are reassuring, but further information about the safety of these valuable antimalarials in pregnancy is needed.
(10 mg/kg). Mefloquine was used in pregnancy up until 1997, when the association with stillbirth was recognized [9] . Atovaquone-proguanil regimen consisted of atovaquone, 20 mg/kg/day, plus proguanil, 8 mg/kg/day for 3 days. b Sometimes given with mefloquine in hyperparasitemic infections. c In later years, a second im dose of artemether (1.6 mg/kg) was used if hyperparasitemic patients deteriorated or showed slow parasite clearance (195th centile) in the first 24 h after receiving orally administered artesunate. d The standard first-line treatment for nonpregnant patients with uncomplicated malaria.
rates [8] . Mefloquine treatment in this area has been linked with the risk of stillbirth [9] , and resistance of P. falciparum to this drug is widespread [10] . We present the results of a prospective evaluation of the safety and efficacy of artemisinin treatments for P. falciparum infections in pregnant women.
PATIENTS AND METHODS
Study site and treatment groups. This study was conducted in the prenatal clinics of the Shoklo Malaria Research Unit (Mae Sot, Thailand). In this hill-forested region, malaria transmission was low and seasonal, and severe malaria was 3 times (95% CI, 1.4-6.2) more common in pregnant compared with nonpregnant women [11] . Maternal malaria in pregnancy was associated with maternal death, anemia, and a reduction in the mean birth weight of the baby [2] . Women were recruited from 2 populations of refugees living in camps for displaced people of the Karen ethnic minority and migrant workers living on the western border of Thailand. These sites were situated within a 60-km radius north and south of the Thai town of Mae Sot. Since 1986, 190% of pregnant women in the camps have attended prenatal clinics on a weekly basis. This has resulted in a significant reduction in maternal death from malaria [12] . Information about malaria and the outcome of pregnancy has been systematically collected prospectively on all women attending the prenatal clinics since 1986. Clinical procedures. Pregnant women who had a microscopically confirmed P. falciparum or mixed (P. falciparum and P. vivax) infection and who gave verbal informed consent to supervised treatment were entered into the study. Women were followed weekly until delivery or until 42 days after treatment was given. At admission, baseline demographic data were collected, and medical and obstetric histories, including a detailed malaria history, were recorded. Physical examination included recording the weight, oral temperature, blood pressure, pulse, fetal heart rate, fundal height, presence of anemia or edema, and spleen and liver measurements. Laboratory investigations at admission included a confirmatory malaria smear and an assessment of hematocrit. Parasitemia was assessed, on Giemsastained thick blood films, as the number of parasites per 500 WBCs or, on thin blood films, as the number of parasites per 1000 RBCs. Women whose hematocrit dropped below 30% were given weekly supplements of ferrous sulphate, 250 mg t.i.d., and folic acid, 5 mg daily. If the hematocrit decreased to 20% and the woman was symptomatic for anemia, a blood transfusion was given after testing the donor blood for HIV, hepatitis B, malaria, and direct cross-match.
Labor and delivery. Women identified as having high-risk pregnancies were asked to deliver in the unit clinic, even though women usually deliver at home with traditional birth attendants. A World Health Organization partogram was completed for all women who gave birth in the unit, and full details of delivery were recorded. Women who delivered at home were followed up by a health visitor at their homes. Newborns were weighed on a Salter scale accurate to 50 g. Newborns had an examination for estimation of gestational age by the Dubowitz method within 5 days of birth. If no Dubowitz examination could be completed, estimated gestational age was calculated (fundal height ϫ ) by a formula developed for this population. If 0.887 ϩ 4.968 no Dubowitz score or fundal height had been recorded, the gestation was estimated from the time of the mother's last menstrual period. For the purpose of comparison, community rates of abortion, stillbirth, low birth weight, and the mean ‫ע‬ SD of birth weight and gestational age from the Dubowitz examinations collected between 1993 and 2000 were used. Antimalarial drug regimens. Patients receiving treatment for P. falciparum infections received artesunate orally (Guilin; People's Republic of China), im administered artemether (Kunming Pharmaceutical Factory), or iv administered artesunate (Guilin; People's Republic of China). Artemisinin treatments were sometimes used in combination with mefloquine (Lariam; Hoffman-La Roche), clindamycin (Pharmacia & Upjohn), atovaquone-proguanil (Malarone; Glaxo-Wellcome), or, inadvertently (i.e., pregnancy was not declared), coartemether (Novartis Pharma; fixed combination of artemether, 20 mg, and lumefantrine, 120 mg). During the 8 years of this study, treatment schedules varied slightly (table 1) .
All drug administrations were supervised. Antimalarial drugs were given with a small amount of sugar water, except the combination of artesunate and atovaquone-proguanil, which was given with milk (8% fat) [13] . If vomiting occurred within 30 min of drug intake, the full dose was repeated. If vomiting occurred between 30 min and 1 h, half of the dose was repeated.
Definitions. Taking of patient histories was useful in distinguishing the first treatment in pregnancy, but it was not possible to distinguish between failure to respond to treatment or reinfection in subsequent episodes because parasite genotyping was not routinely performed. Hence, in this study, treatments have been classified as primary or re-treatment. Use of an artemisinin compound when the woman had not declared her pregnancy was defined as an inadvertent treatment. Hyperparasitemic infections, severe infections, or both were those with a parasitemia of 14% of total RBCs, signs of severe malaria, or both [14] . Parasite reappearance was defined as a positive malaria smear for P. falciparum or mixed infection (P. falciparum and P. vivax) within 42 days from treatment. An episode was considered symptomatic when the woman had fever (137.5ЊC) or a history of fever. Anemia was defined as an hematocrit level !30%. The person-gametocyte-weeks (PGW) was calculated by dividing the number of weeks (during the 7-42-day follow-up) the women had gametocytes after treatment by the number of weeks they were followed, then expressed per 1000 person weeks. Because some women had 11 malaria episode, the PGW was calculated for each episode (maximum of 42 days of follow-up each time). Prematurity was defined as delivery before 37 estimated weeks of pregnancy. Abortion was defined as delivery of a nonviable fetus before 28 weeks of gestation. Stillbirth was defined as delivery of a dead fetus after 28 weeks of gestation, and low birth weight was defined as !2500 g. Adverse effects. Adverse effects were checked daily until the smears were negative for malaria, and the adverse effects were recorded weekly during follow-up. Symptoms present at baseline (i.e., before the start of the treatment) were considered to be attributable to the disease. Symptoms that were not present at admission but appeared up to 42 days after drug treatment began, and before reappearance of parasitemia, were considered as possibly related to the administration of the drug.
Statistical analysis. Data were described by the statistical program SPSS for Windows (Benelux) and Epi Info (Centers for Disease Control and Prevention). Continuous data were compared by Student's t test or the Mann-Whitney U test where appropriate. Categorical data (rates of failure by day 42) were analyzed by the x 2 test. For the survival analysis of the parasitological response, data were compared by use of the KaplanMeier plots and the Mantel-Haenszel log rank test.
RESULTS
From November 1992 to December 2000, 461 women received a total of 539 artemisinin-based treatments during pregnancy. The baseline characteristics of the women at admission are summarized in table 2. The majority of administrations, 310 (57.5%), were for re-treatments (table 3; ). There were P ! .001 384 (71.2%) of 539 episodes treated with 7 days of artesunate alone. More than 95% of all episodes were treated with a 12-14 mg/kg dose resulting in an artesunate dose of (mean ‫ע‬ SD) mg (range, 76-1092 mg) per treatment and a mean 664 ‫ע‬ 116 artesunate dose of mg (range, 76-2744 mg) per 777 ‫ע‬ 335 woman. Artemether was given to 4 women as part of a full treatment course, to 6 women as an extra dose after slow parasite clearance within 24 h after orally administered artesunate treatment for hyperparasitemia, and to 1 woman with severe malaria. The mean dose of artemether per woman was mg (range, 86-607 mg; ). 307 ‫ע‬ 174 n p 11 Clinical and parasitological responses. Seven women did not complete their treatments: 6 discontinued treatment themselves for personal reasons, and in 1 patient, because security in the camp was unstable. The duration of the clinical followup was days (range, 0-46 days), and 161 (35%) of 461 32 ‫ע‬ 12 women delivered during this follow-up period. Overall, 56% of case patients were symptomatic (fever or history of fever) at the time of admission. Fever at admission was present in 92 (18%) of the episodes, and the mean time to fever clearance was days (range, 1-3 days). Days to parasite clearance 1.2 ‫ע‬ 0.5 were unavailable for 47 episodes of malaria, but for the remaining episodes, the mean was days (range, 1-5 1.9 ‫ע‬ 0.8 days). There were 522 episodes with information available on gametocytes. At admission, gametocytes were present in 59 episodes (11.3%). After excluding the episodes where gametocytes were present at admission, in 37 (8%) of 463 episodes, gametocytes developed between day 7 and 42. The PGW after artemisinin treatment was significantly higher for re-treatments compared with primary treatments (  ; table 3 ). A total P p .019 of 77 (14.3%) of 539 episodes developed a vivax infection during the 42 days of the follow-up period.
Treatment efficacy. Overall, parasite reappearance within 42 days occurred in 62 (11.5%) of 539 episodes, with a median reappearance time of 23 days (range, 12-42 days). If we include only women who were treated for uncomplicated malaria with artesunate alone for 7 days, there was a significant difference in the proportion of case patients who experienced reappearance of parasites between the primary treatment and re-treat- ment groups (table 3; ). By use of survival analysis, P p .002 the cumulative failure rate for primary infections was found to be 6.6% (95% CI, 1.0-12.3) compared with the re-treatment rate of 21.7% (95% CI, 15.4-28.0;
; figure 1 ). P p .004 Adverse effects. There were no serious or clinically significant drug-related adverse reactions in any of the pregnant women. One woman developed pruritus on day 2-probably a mild artesunate allergy that was controlled with orally administered chlorpheniramine.
Clinical information was available for 499 (93%) of 539 clinical episodes. All artemisinin treatments were included in the analysis, even when they were used in combination (e.g., with mefloquine, known to be associated with an increased incidence of neuropsychiatric effects) [15] . The proportions of case patients who developed adverse effects between day 7 and day 42 but who did not have the symptom at admission were compared with the proportion of case patients who complained of that symptom at admission (figure 2), and almost all symptoms were reduced significantly ( ). P ! .001 At admission, 418 (91%) of 461 women had hematocrit results, and of these, 242 (58%) were anemic. Of the remaining 176 women, 166 became anemic during follow-up, leaving only 10 women (2%) who never developed anemia. Per episode, we found that there were no significant differences between the primary and treatment groups in the proportion of women with anemia at admission or anemia during follow-up (table  3) . The mean hematocrit level of all episodes of malaria at admission was lower in the re-treatment group, but this difference was not significant ( ). Severe anemia (hemat-P p .098 ocrit level !20%) was more frequent in the re-treatment group than in the primary treatment group (  ; table 3 ). A P p .022 total of 56 women (12.1%) required blood transfusions in this cohort for malaria-related symptomatic anemia.
Pregnancy outcomes. Among the 461 women receiving an artemisinin-based treatment, the outcome of pregnancy was known for 414 women (89%). A total of 386 (93.2%) of these 414 women bore singletons, and 6 (1.5%) bore sets of twins; 20 (4.8%) experienced abortions, and 2 women (0.5%) died. One maternal death was due to severe malaria and anemia; the patient was an 18-year-old woman in her first pregnancy who had been absent from the prenatal clinic the previous week. The other woman died as a result of causes unrelated to malaria. The overall rates of stillbirth and congenital abnormality were not different from the general community rates (table 4) . There were 7 stillbirths (1.8%) among the 386 live-born singletons. There were 3 abnormal infants (0.8%) born among the singletons: 1 infant had anencephaly (table 5), 1 had a small midline epidermoid cyst at the bridge of the nose, and 1 was apparently normal at birth but was born prematurely while the mother was being retreated for acute symptomatic malaria and severe anemia. Among the 7 sets of twins, 1 pregnancy complicated by high blood pressure terminated with placental abruption at 9 months, resulting in stillborn twins. These twins were externally normal, as were the other 6 sets of twins who were all born live. A total of 334 live-born single infants had a birth weight of g (range, 1250-4300 g). There were 171 placentas 2779 ‫ע‬ 482 weighed, with a mean weight of g (range, 200-700 473 ‫ע‬ 91 g). The mean estimated gestational age from Dubowitz examination was available for 234 (70%) of 334 live-born singletons and was weeks (range, 29.1-41.8 weeks). As 39.2 ‫ע‬ 1.8 expected, more of the infants born to mothers affected by malaria and treated with an artemisinin were of low birth weight than were those born to women in the general community (table 4; ). P p .005 There were 44 artemisinin exposures in the first trimester of pregnancy; artemisinin was provided at an estimated gestation time of weeks (range, 3.0-12.9 weeks). Artemisinins 9.2 ‫ע‬ 3.0 were given at this gestation for primary infections in 19 patients (43%) and for re-treatment in 25 patients (57%). Eleven of the primary treatments were inadvertent and accounted for 2% of all the artemisinin treatments given. The first-trimester pregnancies of 44 artemisinin-exposed women ended in delivery for 30 women (68%) and abortion for 10 women (23%), and 4 women (9%) were lost to follow-up. All infants were externally and neurologically normal. Three of the 10 abortions were inevitable at the time the artemisinin treatment was started, so the overall abortion rate for the first trimester was 18.9% (7 of 37 women). The abortion rate for first-trimester exposures is not significantly different from the overall community rate of 12.3% (table 4; ). P p .211 There were 29 deliveries (28 singletons and a set of twins), including 4 stillbirths and 2 neonatal deaths, in women who received artemisinins in the week preceding delivery. For the 11 women who received artemether, 7 delivered normal infants, 2 women were lost to follow-up before outcome was available, 1 woman aborted, and 1 died as a result of severe malaria and anemia.
DISCUSSION
This study highlights the serious adverse effects of malaria in pregnancy for the mother and fetus in areas of low and seasonal malaria transmission. In such areas maternal premunition is low, and ideally chemoprophylaxis should be offered to all pregnant women. However, when malaria is caused by multidrugresistant strains of P. falciparum, there are no effective options for chemoprophylaxis in pregnancy. Early diagnosis and treatment remains the only method of prevention of maternal and fetal morbidity and mortality. The series presented here is, to our knowledge the largest published so far. The artemisinin derivatives, predominantly artesunate, proved effective for primary treatments, with a cumulative failure rate of 7.8% (95% CI, 3.8-11.7). This compares favorably to current cumulative failure rates of 7 days of supervised quinine of 33% (95% CI, 9-57) [7] . The re-treatment cumulative failure rate of 21.4% (95% CI, 15.8-27.0) with artesunate is much better than the only comparable figures available for quinine or mefloquine, 37% and 38%, respectively [8] . These data suggest that the artemisinin derivatives will reduce the number of women whose infections recrudesce or become severe. Another advantage of the artemisinin drugs is their effect on gametocyte carriage [16] , especially when they are used in a primary infection as opposed to a re-treatment episode. Reducing gametocyte carriage has been shown to reduce transmission and the only alternative gametocytocidal drug, primaquine, is contraindicated in pregnancy.
Artemisinins were well tolerated by pregnant women, and adherence to treatment was consequently good. Pregnancy is known for increased rates of reported symptoms [17] , and antimalarials such as quinine have the consistent unpleasant side effects of cinchonism [18] and can cause potentially dangerous hypoglycemia [19] . So it is fortunate that artemisinins have few, if any, adverse effects in pregnant women.
The rates of abortion, congenital abnormality, and stillbirth in this high risk cohort of pregnant women were all within the normal range of their communities. The rate of abortion among women exposed to antimalarials in the first trimester, after excluding women with inevitable abortion, was 19% (7 of 37). This did not differ significantly from the normal community rate, and furthermore, the other 30 (81%) of 37 women went on to deliver normal infants. This suggests that the effects of fetal resorption seen in rodents [6] may not apply in humans given treatment doses of artemisinins-with the caveat that were few early first-trimester exposures. Although the true denominator of exposure is not known, 190% of pregnant women in the camps attend the weekly prenatal clinics, so it is likely that the majority of early-pregnancy exposures to artemisinins were captured within the system. Artesunate used late in pregnancy does not appear to result in problems with initiating breast-feeding. There is no evidence so far of emerging resistance to the artemisinin derivatives. However, they should be used in combination with another drug to prevent the selection of resistant parasites [20] . Further work is needed to identify alternative drugs that are safe in pregnancy and can be combined with the artemisinins. This may allow a more practical 3-day regimen to be identified and would avoid the use of "unprotected" artesunate. Women treated with an artemisinin derivative during pregnancy should have their pregnancy outcome systematically documented so that rare adverse events can be identified.
